Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors.
Eric Y ZhaoEnrique Sanz-GarciaZhihui Amy LiuDerek WongKayla MarshAlbiruni Abdul RazakAnna SpreaficoPhilippe L BedardAaron Richard HansenStéphanie LheureuxDax TortiBernard LamShih Yu Cindy YangJustin M BurgenerPing LuoYong ZengNicholas ChengPhillip AwadallaScott V BratmanPamela S OhashiTrevor J PughLillian L SiuPublished in: Cancer discovery (2024)
Analysis of methylation and fragment length in plasma using cfMeDIP-seq provides a tumor-naive approach to measure ctDNA with results comparable with a tumor-informed bespoke ctDNA. Early kinetics within the first weeks of treatment in methylation and fragment quantity can predict outcomes with pembrolizumab in patients with various advanced solid tumors. This article is featured in Selected Articles from This Issue, p. 897.